Synthaverse (SVE.WA) Osake Kurssi
Synthaverse Kurssi
Liikevaihto on kasvanut 2,2 % vuodessa viimeisten 16 vuoden aikana 42,01 M PLN:een. Osakekohtainen tulos on kasvanut 11,5 % vuodessa viimeisten 15 vuoden aikana. Synthaversen nettomarginaali on nyt −47,4 %, laskenut 10,3 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 6,63 PLN, eli yli nykyhintaa 137,2 %. 5 analyytikosta 4 suosittaa ostoa — kokonaiskonsensus on Osta.
Synthaverse osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Synthaverse liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Synthaverse -osakkeesta
The business model of Biomed Lublin Wytwórnia Surowic i Szczepionek SA is focused on the production and distribution of vaccines, serums, and biological products. As a professional stock website, we provide information on the business strategies and operations of Biomed Lublin Wytwórnia Surowic i Szczepionek SA. This Polish company aims to cater to the healthcare industry by delivering high-quality healthcare solutions through the development and manufacturing of vaccines and serums. Biomed Lublin Wytwórnia Surowic i Szczepionek SA's business model revolves around meeting the growing demands for immunization and contributing to public health both nationally and globally.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Biomed Lublin Wytwornia Surowic i Szczepionek SA in the market are other pharmaceutical companies operating in the vaccine and serum production industry. Some notable competitors include GlaxoSmithKline, Pfizer, Sanofi, Merck & Co., and Johnson & Johnson.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish pharmaceutical company specializing in the development and production of vaccines and serums. With a rich history spanning several decades, Biomed Lublin has emerged as a key player in the healthcare industry. Established in 1950, the company has continuously evolved, leveraging its expertise in immunology and microbiology to create innovative biopharmaceutical solutions. Over the years, Biomed Lublin has contributed significantly to public health, delivering high-quality vaccines to protect against various diseases. Their commitment to research, state-of-the-art facilities, and stringent quality controls has earned Biomed Lublin Wytwornia Surowic i Szczepionek SA a reputation for excellence in the pharmaceutical market.
Biomed Lublin Wytwornia Surowic i Szczepionek SA has achieved several significant milestones. The company has successfully developed and manufactured a range of high-quality vaccines and sera, contributing to the improvement of public health worldwide. It has obtained various regulatory approvals, ensuring the safety and efficacy of its products. Biomed Lublin has also established partnerships with reputable international organizations and pharmaceutical companies, enhancing its global presence in the biopharmaceutical industry. Additionally, the company has invested in research and development, leading to advancements in vaccine production technology and the development of new innovative products. These achievements showcase Biomed Lublin Wytwornia Surowic i Szczepionek SA's dedication to excellence and its commitment to addressing global healthcare challenges.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily present in Poland.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a renowned company that embodies strong values and a clear corporate philosophy. With its dedication to excellence, innovation, and customer satisfaction, Biomed Lublin strives to provide high-quality vaccines and serum products. The company emphasizes transparency, integrity, and responsible corporate citizenship in all its operations. Biomed Lublin's commitment to research and development ensures the continuous improvement of its products, enabling it to contribute significantly to the healthcare industry. By prioritizing safety, efficacy, and ethical business practices, Biomed Lublin Wytwornia Surowic i Szczepionek SA demonstrates its dedication to improving global health and saving lives.
Analyytikot asettavat tällä hetkellä Synthaverse-osakkeelle keskimääräisen tavoitehinnan 6,63 PLN (mediaani: 6,63 PLN), mikä merkitsee +137,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 5 analyytikkoarvioon.
5 analyytikkoa arvioi tällä hetkellä Synthaverse-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Synthaverse-yhtiöltä 47,00 M PLN liikevaihtoa ja −0,40 PLN osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Synthaverse-osake noteerataan hintaan 0,64 EUR (2,80 PLN).
Synthaverse-osake (SVE.WA) on listattuna 5 pörssissä, muun muassa: London (0RKM.L), Frankfurt (6NQ.F), München (6NQ.MU).
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish company specializing in the production of vaccines, serum, and other biological products. The company was established in 1950 and has experienced continuous growth since then. Biomed Lublin is an important member of the Polish biotechnology industry and has established itself as a key supplier of medical products. The company focuses on the production of vaccines, including tetanus, diphtheria, scarlet fever, polio, hepatitis A and B, typhoid, and rabies. Additionally, Biomed Lublin produces serum, antitoxins, and other antibody products that are distributed worldwide. The company's blood products and plasmapheresis products department is also an integral part of its services. Biomed Lublin has multiple state-of-the-art production facilities and the necessary equipment to ensure the quality and effectiveness of its products. It is certified and complies with Good Manufacturing Practices (GMP) standards, ensuring strict quality assurance throughout all phases of product development and manufacturing. Moreover, Biomed Lublin is involved in research and development, collaborating with leading academic institutions in Poland and abroad to create the best possible scientific basis. Exporting its products to countries worldwide is one of the core businesses of Biomed Lublin, with current partner countries including Japan, China, Brazil, Russia, and India. In conclusion, Biomed Lublin is an established biotechnology company with a long history and expertise in the production and distribution of biological products. It has a strong international network and is capable of offering high-quality products at competitive prices.
odotettu liikevaihto Synthaverse on 47,00 M PLN. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Synthaverse on −30,31 M PLN. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Synthaverse:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,99. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Synthaverse-osakkeen arvostusta.
Synthaverse:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,51. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Synthaverse-osakkeen arvostuskennuslukuna.
Synthaverse:n Eulpool-laatuscore on 1/10.
Synthaverse:n ISIN on PLBMDLB00018. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Synthaverse:n WKN on A1J10U. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Synthaverse:n ticker on SVE.WA. Tämä pörssinoteeraus käytetään Synthaverse-osakkeiden kauppaan pörssissä.
Synthaverse osake
Synthaverse vertaisryhmä
Synthaverse Ticker
Synthaverse FIGI
Kaikki tunnusluvut ja syvällinen analyysi Synthaverse:sta
Meidän osakeanalyysimme Synthaverse-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Synthaverse:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: